These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9085405)

  • 61. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers.
    Bradwejn J; LeGrand JM; Koszycki D; Bates JH; Bourin M
    Am J Psychiatry; 1998 Feb; 155(2):280-2. PubMed ID: 9464212
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings.
    Bradwejn J; Koszycki D; Payeur R; Bourin M; Borthwick H
    Am J Psychiatry; 1992 Jul; 149(7):962-4. PubMed ID: 1609879
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study.
    Eser D; Schüle C; Baghai T; Floesser A; Krebs-Brown A; Enunwa M; de la Motte S; Engel R; Kucher K; Rupprecht R
    Psychopharmacology (Berl); 2007 Jul; 192(4):479-87. PubMed ID: 17318504
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
    Pande AC; Greiner M; Adams JB; Lydiard RB; Pierce MW
    Biol Psychiatry; 1999 Sep; 46(6):860-2. PubMed ID: 10494457
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone.
    de Beurs E; van Balkom AJ; Lange A; Koele P; van Dyck R
    Am J Psychiatry; 1995 May; 152(5):683-91. PubMed ID: 7726307
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical effects of fluvoxamine on panic symptomatology.
    Pols H; Zandergen J; de Loof C; Fernandez I; Griez E
    Acta Psychiatr Belg; 1993; 93(3):169-77. PubMed ID: 8030430
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Experimental panic provocation in healthy man-a translational role in anti-panic drug development?
    Kellner M
    Dialogues Clin Neurosci; 2011; 13(4):485-93. PubMed ID: 22275853
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men.
    Dépôt M; Merani S; Bradwejn J; Mukherjee J; Caillé J; Gutkowska J; Caillé G
    J Psychiatry Neurosci; 1998 Nov; 23(5):298-304. PubMed ID: 9846035
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
    Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Neuropharmacological and genetic study of panic disorder].
    Akiyoshi J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):93-9. PubMed ID: 10495983
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Glyoxalase-I mRNA expression and CCK-4 induced panic attacks.
    Eser D; Uhr M; Leicht G; Asmus M; Länger A; Schüle C; Baghai TC; Mulert C; Rupprecht R
    J Psychiatr Res; 2011 Jan; 45(1):60-3. PubMed ID: 20542521
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Serotonin-influencing drugs in the treatment of panic disorder.
    Westenberg HG; den Boer JA
    Psychopathology; 1989; 22 Suppl 1():68-77. PubMed ID: 2498967
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of low-dose cholecystokinin on respiratory function in healthy volunteers.
    Schruers K; Caycedo N; Overbeek T; Büchold H; Bourin M; Griez E
    Eur Neuropsychopharmacol; 2000 Sep; 10(5):419-21. PubMed ID: 10974616
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The abrupt discontinuation of fluvoxamine in patients with panic disorder.
    Black DW; Wesner R; Gabel J
    J Clin Psychiatry; 1993 Apr; 54(4):146-9. PubMed ID: 8486592
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers.
    Koszycki D; Bradwejn J; Bourin M
    Eur Neuropsychopharmacol; 1991 May; 1(2):137-41. PubMed ID: 1821703
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Copeptin in CCK-4-induced panic in healthy man: Sexual dimorphisms in secretion pattern and panic response, but no correlation of copeptin with panic symptoms.
    Kellner M; Zwanzger P; Rupprecht R; Eser D; Yassouridis A; Wiedemann K
    Psychoneuroendocrinology; 2019 Dec; 110():104433. PubMed ID: 31525566
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
    Kellner M; Muhtz C; Stark K; Yassouridis A; Arlt J; Wiedemann K
    Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers.
    Aluoja A; Shlik J; Vasar V; Kingisepp PH; Jagomägi K; Vasar E; Bradwejn J
    Psychiatry Res; 1997 Jan; 66(1):59-67. PubMed ID: 9061804
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Missense mutation of the cholecystokinin B receptor gene: lack of association with panic disorder.
    Kato T; Wang ZW; Zoega T; Crowe RR
    Am J Med Genet; 1996 Jul; 67(4):401-5. PubMed ID: 8837709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.